Emerging evidence suggests that CDK4/6 inhibitors exert antitumour activity through other mechanisms beyond the acknowledged ability to block the cell cycle, including the induction of stress response pathways, the reprogramming of cancer cell metabolism, the modulation of the tumour microenvironment, the enhancement of the antitumour immune responses and the reduction of immune evasion. The gene discussed is CDK4; the disease is neoplasm.